Video: Perrigo’s Pivot to OTC Products Produces a Bulwark Against Economic Uncertainty
|November 20, 2023|
- 3.63% dividend yield, we believe the company’s earnings will grow by 10% per year.
- Repositioning toward consumer-facing health brand progressing with divestitures and acquisitions. Power player in consumer staples.
- Opill prescription birth control approved for moving to OTC (Over The Counter) usage.
- Baby formula operation is undergoing expansion to allow for an additional 100 million units in volume per year, in the face of global shortages of baby formula.